Loading publications…
The last 5 uploaded publications
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal, Daniela Sia, Carla Montironi, Wei Qiang Leow, Roger Esteban-Fabró, Roser Pinyol, Miguel Torres‐Martín, Laia Bassaganyas, Agrin Moeini, Judit Peix, Laia Cabellos, Miho Maeda, Carlos Villacorta-Martín, Parissa Tabrizian, Leonardo Rodríguez‐Carunchio, Giancarlo Castellano, Christine Sempoux, Beatriz Mínguez, Timothy M. Pawlik, Ismaïl Labgaa, Lewis R. Roberts, Manel Solé, Maria Isabel Fiel, Swan N. Thung, Josep Fuster, Sasan Roayaie, Augusto Villanueva, M. Schwartz, Josep M. Llovet (2020). Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 73(2), pp. 315-327, DOI: 10.1016/j.jhep.2020.03.008.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), pp. 2093-2106, DOI: 10.1136/gutjnl-2021-326259.
Article145 days agoHuman-correlated genetic models identify precision therapy for liver cancer
Miryam Müller, Stephanie May, H. G. HALL, Timothy J. Kendall, Lynn McGarry, Lauriane Blukacz, Sandro Nuciforo, Αναστασία Γεωργακοπούλου, Thomas Jamieson, Narisa Phinichkusolchit, Sandeep Dhayade, Toshiyasu Suzuki, Júlia Huguet‐Pradell, Ian R. Powley, Leah Officer-Jones, Rachel Pennie, Roger Esteban-Fabró, Albert Gris‐Oliver, Roser Pinyol, George Skalka, Jack Leslie, Matthew Hoare, Joep Sprangers, Gaurav Malviya, Agata Mackintosh, Emma Johnson, Misti McCain, John Halpin, Christos Kiourtis, Colin Nixon, Graeme M. Clark, William R. Clark, Robin Shaw, Ann Hedley, Thomas M. Drake, Ee Hong Tan, Matt Neilson, Daniel J. Murphy, David Y. Lewis, Helen L. Reeves, John Le Quesne, Derek A. Mann, Leo M. Carlin, Karen Blyth, Josep M. Llovet, Markus H. Heim, Owen J. Sansom, Crispin Miller, Thomas G. Bird (2025). Human-correlated genetic models identify precision therapy for liver cancer. Nature, DOI: 10.1038/s41586-025-08585-z.
Article145 days agoMolecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
Robert Montal, Carmen Andreu-Oller, Laia Bassaganyas, Roger Esteban-Fabró, Sebastián Morán, Carla Montironi, Agrin Moeini, Roser Pinyol, Judit Peix, Laia Cabellos, Augusto Villanueva, Daniela Sia, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet (2019). Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 121(4), pp. 340-343, DOI: 10.1038/s41416-019-0513-7.
Article145 days agoCabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Roger Esteban-Fabró, Catherine E. Willoughby, Marta Piqué‐Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix, Laura Torrens, Agavni Mesropian, Ugne Balaseviciute, Francesc Miró‐Mur, Vincenzo Mazzaferro, Roser Pinyol, Josep M. Llovet (2022). Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 28(11), pp. 2449-2460, DOI: 10.1158/1078-0432.ccr-21-2517.
Article145 days ago